A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.

@article{Chen2015AKM,
  title={A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.},
  author={J Z S Chen and C Hsu and N. J. Chiang and C S Tsai and H H Tsou and S F Huang and Li-Yuan Bai and I C Chang and H. S. Shiah and Ching Liang Ho and C J Yen and K D Lee and C F Chiu and K M Rau and M S Yu and Ying-ying Yang and R K Hsieh and J. Y. Chang and Yen-Shen Shan and Yee Chao and L. T. Tai-Hua Chen},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2015},
  volume={26 5},
  pages={943-9}
}
BACKGROUND Previous clinical trials have not proved that adding epidermal growth factor receptor inhibitors to chemotherapy confers a survival benefit for patients with advanced biliary tract cancer (ABTC). Whether the KRAS mutation status of tumor cells confounded the results of past studies is unknown. PATIENTS AND METHODS ABTC patients stratified by KRAS status, Eastern Cooperative Oncology Group performance status, and primary tumor location were randomized 1 : 1 to receive GEMOX (800 mg… CONTINUE READING